HONG KONG – Nagoya, Japan-based Askat Inc. has signed a $1.2 billion licensing deal for two of its immune-oncology compounds with Arrys Therapeutics Inc., of Cambridge, Mass. Arrys was granted research, development and marketing rights for Askat's two prostaglandin E2 receptor 4 (EP4) antagonists, AAT-007 and AAT-008, in the global market excluding China.
HONG KONG – Nagoya, Japan-based Askat Inc. has signed a $1.2 billion licensing deal for two of its immune-oncology compounds with Arrys Therapeutics Inc., of Cambridge, Mass. Arrys was granted research, development and marketing rights for Askat's two prostaglandin E2 receptor 4 (EP4) antagonists, AAT-007 and AAT-008, in the global market excluding China.
HONG KONG – Hong Kong-based has signed a co-development deal with Beijing Shenogen Pharma Group Ltd. to combine Lee's PD-L1 antibody with Shenogen's lead traditional Chinese medicine-derived small-molecule drug.
HONG KONG – Hong Kong-based Lee's Pharmaceutical Holdings Ltd. has signed a co-development deal with Beijing Shenogen Pharma Group Ltd. to combine Lee's PD-L1 antibody with Shenogen's lead traditional Chinese medicine-derived small-molecule drug.
HONG KONG – Beigene Ltd. is advancing its small-molecule Bruton's tyrosine kinase (BTK) inhibitor BGB-3111 into two more global clinical trials, further exploring the efficacy of the drug candidate in treating B-cell cancers.
HONG KONG – A year and a half after reports of illegal vaccine sales prompted investigation by China's CFDA, a recent recall involving vaccines of substandard quality has further eroded public trust in the country toward drug safety and raised concerns of the government's loophole-ridden supervision of the space.
